RARE:NASDAQ
Ultragenyx Pharmaceutical Inc
$16.08
arrow_downward
-1.17%(-0.19) 1 دن
13 نومبر, 4:00:00 PM GMT -5 · USD
search
تمام علامات
| علامت | قیمت | تبدیلی | % تبدیلی |
|---|
insights_autoRARE کے لیے سرفہرست بصیرتیں تخلیق کی جا رہی ہیں...
کھولیں
$16.30
اعلی
$16.32
کم
$15.85
مارکیٹ کی سرمایہ کاری
1.64 ارب
اوسط والیوم
37.07 لاکھ
والیوم
16.79 لاکھ
52 ہفتے میں اعلی
$39.89
52 ہفتے کا کم
$12.73
EPS
-$5.19
بی ٹا
0.37
بقایہ شیئرز
10.19 کروڑ
ملازمین کی تعداد
1 ہزار
کھولیں
$16.30
اعلی
$16.32
کم
$15.85
مارکیٹ کی سرمایہ کاری
1.64 ارب
اوسط والیوم
37.07 لاکھ
والیوم
16.79 لاکھ
52 ہفتے میں اعلی
$39.89
52 ہفتے کا کم
$12.73
EPS
-$5.19
بی ٹا
0.37
بقایہ شیئرز
10.19 کروڑ
ملازمین کی تعداد
1 ہزار
خبریں اور کہانیاں
ویب ذرائع اور خبروں کے پارٹنرز سے
24/7 Wall St.
·
6 منٹ پہلے
He Thinks His $200,000 S&P 500 401(k) Spreads His AI Risk. Two Alphabet Share Classes Put $10,380 in One Company. A 20% Drop Could Cost Him $2,076
TradingView
·
4 گھنٹے پہلے
SpaceX's S&P 500 bid gets new life as Elon Musk pitches Tesla merger
The Motley Fool
·
7 گھنٹے پہلے
Prediction: This Small-Cap Value ETF Will Beat the S&P 500 Over the Next 10 Years
Traders Union
·
4 گھنٹے پہلے
Michael Kantro: Institutional investors focus on stock picking as S&P 500 targets have lost relevance
پروفائل
Ultragenyx Pharmaceutical Inc. is an American biopharmaceutical company involved in the research and development of novel products for treatment of rare and ultra-rare genetic diseases for which there are typically no approved treatments and high unmet medical need. The company works with multiple drug modalities including biologics, small molecule, gene therapies, and ASO and mRNAs in the disease categories of bone, endocrine, metabolic, muscle and CNS diseases.
Ultragenyx is based in Novato, CA and Brisbane, CA and has a presence in the Boston area, including a gene therapy plant under construction as of 2021. The company’s Latin American headquarters is located in Miami.
Ultragenyx collaborates on product development with other companies including GeneTX, Kyowa Hakko Kirin, Mereo Biopharma and Daiichi Sankyo. Ultragenyx has three products Burosumab, Triheptanoin and Vestronidase alfa that have received FDA approval and several others currently in clinical trials. The company also holds the non-US commercial rights to Regeneron’s evinacumab-dgnb, which is approved by the FDA and EMA. Wikipedia
Ultragenyx Pharmaceutical Inc کے بارے میں
CEOایمل کاکیس
ملازمین1.37 ہزار
تاریخ قیام2010
ہیڈ کواٹرزNovato, کیلیفورنیا, ریاستہائے متحدہ
سیکٹرHealth Care
انڈسٹری-
ویب سائٹultragenyx.com